NPCE Stock Summary and Trading Ideas (Neuropace | NASDAQ:NPCE)

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

Neuropace trades on the NASDAQ stock market under the symbol NPCE.

As of December 11, 2025, NPCE stock price declined to $16.46 with 12,203 million shares trading.

NPCE has a beta of 0.28, meaning it tends to be less sensitive to market movements. NPCE has a correlation of 0.00 to the broad based SPY ETF.

NPCE has a market cap of $548.25 million. This is considered a Small Cap stock.

Last quarter Neuropace reported $27 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.09.

In the last 3 years, NPCE traded as high as $18.98 and as low as $1.22.

The top ETF exchange traded funds that NPCE belongs to (by Net Assets): IWM, VTI, IWO, VXF, VTWO.

NPCE has outperformed the market in the last year with a return of +43.0%, while the SPY ETF gained +14.5%. In the last 3 month period, NPCE beat the market returning +70.2%, while SPY returned +4.9%. However, in the most recent 2 weeks NPCE has underperformed the stock market by returning -0.2%, while SPY returned +0.4%.

NPCE support price is $16.01 and resistance is $17.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NPCE shares will trade within this expected range on the day.